Menu
Search
|

Menu

Close
X

Neurocrine Biosciences Inc NBIX.OQ (NASDAQ Stock Exchange Global Select Market)

89.98 USD
-1.73 (-1.89%)
As of Nov 16
chart
Previous Close 91.71
Open 90.65
Volume 314,540
3m Avg Volume 274,990
Today’s High 92.66
Today’s Low 89.79
52 Week High 126.15
52 Week Low 67.37
Shares Outstanding (mil) 88.22
Market Capitalization (mil) 5,508.56
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.71 Mean rating from 14 analysts

KEY STATS

Revenue (mm, USD)
FY18
320
FY17
162
FY16
15
FY15
20
EPS (USD)
FY18
-0.008
FY17
-1.627
FY16
-1.626
FY15
-1.037
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
869.54
5.69
Price to Book (MRQ)
vs sector
15.95
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
104.47
15.71
LT Debt to Equity (MRQ)
vs sector
104.47
11.53
Return on Investment (TTM)
vs sector
-38.94
15.05
Return on Equity (TTM)
vs sector
-60.54
16.62

EXECUTIVE LEADERSHIP

William Rastetter
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Kevin Gorman
Chief Executive Officer, Director, Since 2017
Salary: $575,000.00
Bonus: $345,000.00
Matthew Abernethy
Chief Financial Officer, Since 2017
Salary: $38,231.00
Bonus: $20,071.00
Eric Benevich
Chief Commercial Officer, Since 2015
Salary: $218,532.00
Bonus: $109,300.00
Haig Bozigian
Chief Development Officer, Since 2012
Salary: $381,600.00
Bonus: $190,800.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

12780 El Camino Real
SAN DIEGO   CA   92130-2042

Phone: +1858.6177600

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

SPONSORED STORIES